Literature DB >> 30349988

Dihydropyrimidine Dehydrogenase Deficiency: Homozygosity for an Extremely Rare Variant in DPYD due to Uniparental Isodisomy of Chromosome 1.

André B P van Kuilenburg1, Judith Meijer2, Rutger Meinsma2, Belén Pérez-Dueñas3,4, Marielle Alders2, Zahurul A Bhuiyan5, Rafael Artuch3, Raoul C M Hennekam2.   

Abstract

Dihydropyrimidine dehydrogenase (DPD) deficiency is a rare autosomal recessive disorder of the pyrimidine degradation pathway and can lead to intellectual disability, motor retardation, and seizures. Genetic variations in DPYD have also emerged as predictive risk factors for severe toxicity in cancer patients treated with fluoropyrimidines. We recently observed a child born to non-consanguineous parents, who demonstrated seizures, cognitive impairment, language delay, and MRI abnormalities and was found to have marked thymine-uraciluria. No residual DPD activity could be detected in peripheral blood mononuclear cells. Molecular analysis showed that the child was homozygous for the very rare c.257C > T (p.Pro86Leu) variant in DPYD. Functional analysis of the recombinantly expressed DPD mutant showed that the DPD mutant carrying the p.Pro86Leu did not possess any residual DPD activity. Carrier testing in parents revealed that the father was heterozygous for the variant but unexpectedly the mother did not carry the variant. Microsatellite repeat testing with markers covering chromosome 1 showed that the DPD deficiency in the child is due to paternal uniparental isodisomy. Our report thus extends the genetic spectrum underlying DPYD deficiency.

Entities:  

Keywords:  DPYD; Dihydropyrimidine dehydrogenase; Pyrimidines; Uniparental isodisomy

Year:  2018        PMID: 30349988      PMCID: PMC6336675          DOI: 10.1007/8904_2018_138

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  13 in total

1.  Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil.

Authors:  M R Johnson; R B Diasio
Journal:  Adv Enzyme Regul       Date:  2001

2.  Dihydropyrimidine dehydrogenase deficiency in two malaysian siblings with abnormal MRI findings.

Authors:  Bee Chin Chen; Rowani Mohd Rawi; Rutger Meinsma; Judith Meijer; Raoul C M Hennekam; André B P van Kuilenburg
Journal:  Mol Syndromol       Date:  2014-09-25

3.  Defects in pyrimidine degradation identified by HPLC-electrospray tandem mass spectrometry of urine specimens or urine-soaked filter paper strips.

Authors:  H van Lenthe; A B van Kuilenburg; T Ito; A H Bootsma; A van Cruchten; Y Wada; A H van Gennip
Journal:  Clin Chem       Date:  2000-12       Impact factor: 8.327

4.  Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure.

Authors:  André B P van Kuilenburg; Doreen Dobritzsch; Rutger Meinsma; Janet Haasjes; Hans R Waterham; Malgorzata J M Nowaczyk; George D Maropoulos; Guido Hein; Hermann Kalhoff; Jean M Kirk; Holger Baaske; Anne Aukett; John A Duley; Kate P Ward; Ylva Lindqvist; Albert H van Gennip
Journal:  Biochem J       Date:  2002-05-15       Impact factor: 3.857

Review 5.  Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency.

Authors:  A B Van Kuilenburg; P Vreken; N G Abeling; H D Bakker; R Meinsma; H Van Lenthe; R A De Abreu; J A Smeitink; H Kayserili; M Y Apak; E Christensen; I Holopainen; K Pulkki; D Riva; G Botteon; E Holme; M Tulinius; W J Kleijer; F A Beemer; M Duran; K E Niezen-Koning; G P Smit; C Jakobs; L M Smit; A H Van Gennip
Journal:  Hum Genet       Date:  1999-01       Impact factor: 4.132

6.  Analysis of severely affected patients with dihydropyrimidine dehydrogenase deficiency reveals large intragenic rearrangements of DPYD and a de novo interstitial deletion del(1)(p13.3p21.3).

Authors:  André B P van Kuilenburg; Judith Meijer; Adri N P M Mul; Raoul C M Hennekam; Jan M N Hoovers; Christine E M de Die-Smulders; Peter Weber; Andrea Capone Mori; Jörgen Bierau; Brian Fowler; Klaus Macke; Jörn Oliver Sass; Rutger Meinsma; Julia B Hennermann; Peter Miny; Lida Zoetekouw; Raymon Vijzelaar; Joost Nicolai; Bauke Ylstra; M Estela Rubio-Gozalbo
Journal:  Hum Genet       Date:  2009-03-19       Impact factor: 4.132

7.  Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.

Authors:  André B P Van Kuilenburg; Rutger Meinsma; Lida Zoetekouw; Albert H Van Gennip
Journal:  Int J Cancer       Date:  2002-09-20       Impact factor: 7.396

8.  Cytogenetic contribution to uniparental disomy (UPD).

Authors:  Thomas Liehr
Journal:  Mol Cytogenet       Date:  2010-03-29       Impact factor: 2.009

Review 9.  Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.

Authors:  André B P van Kuilenburg
Journal:  Eur J Cancer       Date:  2004-05       Impact factor: 9.162

10.  Head imaging abnormalities in dihydropyrimidine dehydrogenase deficiency.

Authors:  G M Enns; A J Barkovich; A B P van Kuilenburg; M Manning; T Sanger; D R Witt; A H van Gennip
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

View more
  1 in total

1.  DPD status and fluoropyrimidines-based treatment: high activity matters too.

Authors:  Emmanuel Chamorey; Eric Francois; Marie-Christine Etienne; Jean-Marc Ferrero; Frederic Peyrade; Emmanuel Barranger; Alexandre Bozec; Rémy Largillier; Ophelie Cassuto; Julien Viotti; Renaud Schiappa; Gérard Milano
Journal:  BMC Cancer       Date:  2020-05-18       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.